The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

This is the unique (3,7)-cage, meaning a graph such that each vertex has 3 neighbors and the shortest cycle has length 7.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

A perfect number is the sum of its proper factors such as 6 = 3 + 2 + 1 or 28 = 14 + 7 + 4 + 2 ... and the same number of them meet at each vertex. (Think cubes and dodecahedra.) ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...